NASDAQ:ATNX - Athenex Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $12.64 +0.14 (+1.12 %) (As of 02/15/2019 04:00 PM ET)Previous Close$12.50Today's Range$12.38 - $12.6652-Week Range$9.83 - $20.90Volume168,100 shsAverage Volume214,716 shsMarket Capitalization$845.54 millionP/E Ratio-5.42Dividend YieldN/ABeta0.13 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom. In addition, the company offers Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis; and KX-02 that is Phase I clinical trial for solid tumor patients. Further, it is developing intranasal formulations of granisetron, a 5-hydroxytryptamine 3 receptor antagonist to prevent chemotherapy-induced nausea and vomiting; and dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. has a strategic partnership with Hanmi Pharmaceuticals to develop their Orascovery and KX-01 programs. The company was founded in 2003 and is headquartered in Buffalo, New York. Receive ATNX News and Ratings via Email Sign-up to receive the latest news and ratings for ATNX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATNX Previous Symbol CUSIPN/A Webwww.athenex.com Phone716-427-2950Debt Debt-to-Equity Ratio0.30 Current Ratio4.46 Quick Ratio3.86Price-To-Earnings Trailing P/E Ratio-5.42 Forward P/E Ratio-6.38 P/E GrowthN/A Sales & Book Value Annual Sales$38.04 million Price / Sales22.23 Cash FlowN/A Price / Cash FlowN/A Book Value$1.45 per share Price / Book8.72Profitability EPS (Most Recent Fiscal Year)($2.32) Net Income$-131,170,000.00 Net Margins-143.42% Return on Equity-71.94% Return on Assets-49.55%Miscellaneous Employees477 Outstanding Shares66,894,000Market Cap$845.54 million OptionableOptionable Athenex (NASDAQ:ATNX) Frequently Asked Questions What is Athenex's stock symbol? Athenex trades on the NASDAQ under the ticker symbol "ATNX." How were Athenex's earnings last quarter? Athenex Inc (NASDAQ:ATNX) announced its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.58) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.10. The business had revenue of $11.57 million for the quarter. Athenex had a negative net margin of 143.42% and a negative return on equity of 71.94%. View Athenex's Earnings History. When is Athenex's next earnings date? Athenex is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Athenex. What price target have analysts set for ATNX? 3 analysts have issued 1 year price targets for Athenex's shares. Their forecasts range from $15.00 to $30.00. On average, they expect Athenex's share price to reach $24.00 in the next twelve months. This suggests a possible upside of 89.9% from the stock's current price. View Analyst Price Targets for Athenex. What is the consensus analysts' recommendation for Athenex? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athenex. Has Athenex been receiving favorable news coverage? News articles about ATNX stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Athenex earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. Who are some of Athenex's key competitors? Some companies that are related to Athenex include HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Akcea Therapeutics (AKCA), Arena Pharmaceuticals (ARNA) and Endo International (ENDP). Who are Athenex's key executives? Athenex's management team includes the folowing people: Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D., Chairman & CEO (Age 59)Mr. Jeffrey M. Yordon, COO & Pres of Athenex Pharmaceutical Division (Age 70)Dr. Rudolf Kwan M.D., M.B., B.S., Exec. VP & Chief Medical Officer (Age 66)Mr. Kam-Chung Leung GBS, LLD, OBE, JP, Strategic & Bus. Advisor (Age 67)Dr. Allen Barnett, Co-Founder & Pres Emeritus When did Athenex IPO? (ATNX) raised $72 million in an IPO on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager. Who are Athenex's major shareholders? Athenex's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (7.62%), BlackRock Inc. (5.41%), Hsbc Holdings PLC (1.37%), Northern Trust Corp (0.81%), Geode Capital Management LLC (0.73%) and Diag Capital Management LP (0.64%). Company insiders that own Athenex stock include Jeffrey Yordon, Jinn Wu, Johnson Yiu Nam Lau, Manson Fok, Randoll Sze, Rudolf Kwan, Sheldon Trainor-Degirolamo and Song-Yi Zhang. View Institutional Ownership Trends for Athenex. Which major investors are selling Athenex stock? ATNX stock was sold by a variety of institutional investors in the last quarter, including Hsbc Holdings PLC, Creative Planning, Northpointe Capital LLC, MetLife Investment Advisors LLC, Northern Trust Corp, California Public Employees Retirement System and Virtus ETF Advisers LLC. Company insiders that have sold Athenex company stock in the last year include Sheldon Trainor-Degirolamo and Song-Yi Zhang. View Insider Buying and Selling for Athenex. Which major investors are buying Athenex stock? ATNX stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Diag Capital Management LP, Citigroup Inc., Geode Capital Management LLC, BlackRock Inc., Jaffetilchin Investment Partners LLC, Rhumbline Advisers and Prudential Financial Inc.. Company insiders that have bought Athenex stock in the last two years include Jeffrey Yordon, Jinn Wu, Johnson Yiu Nam Lau, Manson Fok, Randoll Sze, Rudolf Kwan and Song-Yi Zhang. View Insider Buying and Selling for Athenex. How do I buy shares of Athenex? Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Athenex's stock price today? One share of ATNX stock can currently be purchased for approximately $12.64. How big of a company is Athenex? Athenex has a market capitalization of $845.54 million and generates $38.04 million in revenue each year. The company earns $-131,170,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Athenex employs 477 workers across the globe. What is Athenex's official website? The official website for Athenex is http://www.athenex.com. How can I contact Athenex? Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at 716-427-2950. MarketBeat Community Rating for Athenex (NASDAQ ATNX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 183 (Vote Outperform)Underperform Votes: 179 (Vote Underperform)Total Votes: 362MarketBeat's community ratings are surveys of what our community members think about Athenex and other stocks. Vote "Outperform" if you believe ATNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/15/2019 by MarketBeat.com StaffFeatured Article: What are convertible shares?